Statistics in Biopharmaceutical Research
Taylor and Francis Ltd.
United Kingdom
journal
SJR by Edition
Subject Categories
- Pharmaceutical ScienceQ1
- Statistics and ProbabilityQ1
Areas: Mathematics · Pharmacology, Toxicology and Pharmaceutics
Most published research topics
Source: OpenAlex
Publication Statistics
Documents per Year
Detailed Information
ISSN
1946-6315
SJR Best Quartile
Q1
Region
Western Europe
Citations per Document (2 years)
1.36
References per Document
29.25
Coverage
2011-2026
Scope
Statistics in Biopharmaceutical Research ( SBR), publishes articles that focus on the needs of researchers and applied statisticians in biopharmaceutical industries; academic biostatisticians from schools of medicine, veterinary medicine, public health, and pharmacy; statisticians and quantitative analysts working in regulatory agencies (e.g., U.S. Food and Drug Administration and its counterpart in other countries); statisticians with an interest in adopting methodology presented in this journal to their own fields; and nonstatisticians with an interest in applying statistical methods to biopharmaceutical problems. Statistics in Biopharmaceutical Research accepts papers that discuss appropriate statistical methodology and information regarding the use of statistics in all phases of research, development, and practice in the pharmaceutical, biopharmaceutical, device, and diagnostics industries. Articles should focus on the development of novel statistical methods, novel applications of current methods, or the innovative application of statistical principles that can be used by statistical practitioners in these disciplines. Areas of application may include statistical methods for drug discovery, including papers that address issues of multiplicity, sequential trials, adaptive designs, etc.; preclinical and clinical studies; genomics and proteomics; bioassay; biomarkers and surrogate markers; models and analyses of drug history, including pharmacoeconomics, product life cycle, detection of adverse events in clinical studies, and postmarketing risk assessment; regulatory guidelines, including issues of standardization of terminology (e.g., CDISC), tolerance and specification limits related to pharmaceutical practice, and novel methods of drug approval; and detection of adverse events in clinical and toxicological studies. Tutorial articles also are welcome.
Metrics from SCImago Journal Rank 2025. View on SCImago